# A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

> **NCT05444257** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 822 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-121/TEZ/D-IVA

## Key facts

- **NCT ID:** NCT05444257
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-08
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 822 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05444257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05444257, "A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05444257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*